Northwest Bioth Cmn (NWBO): Price and Financial Metrics


Northwest Bioth Cmn (NWBO): $0.72

-0.01 (-1.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NWBO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NWBO POWR Grades

  • Sentiment is the dimension where NWBO ranks best; there it ranks ahead of 52.57% of US stocks.
  • The strongest trend for NWBO is in Quality, which has been heading up over the past 177 days.
  • NWBO's current lowest rank is in the Growth metric (where it is better than 1.57% of US stocks).

NWBO Stock Summary

  • With a price/sales ratio of 707.72, NORTHWEST BIOTHERAPEUTICS INC has a higher such ratio than 99.31% of stocks in our set.
  • NWBO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 5.9% of US stocks.
  • Revenue growth over the past 12 months for NORTHWEST BIOTHERAPEUTICS INC comes in at -27.98%, a number that bests just 6.64% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to NORTHWEST BIOTHERAPEUTICS INC, a group of peers worth examining would be WATT, SDGR, MNTS, CLXT, and ENTX.
  • Visit NWBO's SEC page to see the company's official filings. To visit the company's web site, go to www.nwbio.com.

NWBO Valuation Summary

  • In comparison to the median Healthcare stock, NWBO's EV/EBIT ratio is 26.26% higher, now standing at 12.5.
  • NWBO's EV/EBIT ratio has moved up 12.3 over the prior 243 months.

Below are key valuation metrics over time for NWBO.

Stock Date P/S P/B P/E EV/EBIT
NWBO 2023-01-20 701.9 -7.0 13.5 12.5
NWBO 2023-01-19 701.9 -7.0 13.5 12.5
NWBO 2023-01-18 723.2 -7.2 13.9 12.9
NWBO 2023-01-17 707.7 -7.1 13.6 12.6
NWBO 2023-01-13 707.7 -7.1 13.6 12.6
NWBO 2023-01-12 712.5 -7.1 13.7 12.7

NWBO Growth Metrics

    Its year over year cash and equivalents growth rate is now at -6.76%.
  • Its 4 year revenue growth rate is now at 480.44%.
  • Its 4 year net income to common stockholders growth rate is now at 103.65%.
NWBO's revenue has moved down $1,324,000 over the prior 33 months.

The table below shows NWBO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.086 -55.172 56.586
2022-06-30 1.23 -46.067 134.957
2022-03-31 1.169 -38.018 169.035
2021-12-31 1.005 -38.299 179.126
2021-09-30 1.508 -37.256 -234.493
2021-06-30 1.374 -38.265 -474.108

NWBO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NWBO has a Quality Grade of C, ranking ahead of 27.35% of graded US stocks.
  • NWBO's asset turnover comes in at 0.045 -- ranking 328th of 682 Pharmaceutical Products stocks.
  • EDSA, BLCM, and GLYC are the stocks whose asset turnover ratios are most correlated with NWBO.

The table below shows NWBO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.045 1 1.610
2021-03-31 0.036 1 2.337
2020-12-31 0.061 1 3.470
2020-09-30 0.112 1 3.430
2020-06-30 0.190 1 1.815
2020-03-31 0.245 1 -0.306

NWBO Stock Price Chart Interactive Chart >

Price chart for NWBO

NWBO Price/Volume Stats

Current price $0.72 52-week high $2.05
Prev. close $0.73 52-week low $0.39
Day low $0.72 Volume 1,293,200
Day high $0.74 Avg. volume 1,850,728
50-day MA $0.84 Dividend yield N/A
200-day MA $0.78 Market Cap 769.11M

Northwest Bioth Cmn (NWBO) Company Bio


Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.


NWBO Latest News Stream


Event/Time News Detail
Loading, please wait...

NWBO Latest Social Stream


Loading social stream, please wait...

View Full NWBO Social Stream

Latest NWBO News From Around the Web

Below are the latest news stories about NORTHWEST BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate NWBO as an investment opportunity.

NWBO Stock Alert: Northwest Bio Slams Citadel Securities in New Lawsuit

Shares of NWBO stock are rallying on Thursday, as Northwest Biotherapeutics sues a number of Wall Street firms for stock manipulation.

Bret Kenwell on InvestorPlace | December 1, 2022

Northwest Bio Accuses Market Makers of Share Price Manipulation

Northwest Biotherapeutics (NWBO) is suing Citadel Securities, Susquehanna International, and other names on the Street for manipulating its share price via illegal trades, according to the Wall Street Journal. The biotechnology company has accused market-making firms of ‘spoofing’ the order book (a flurry of orders that are canceled immediately) which led to a decline in its share price. NWBO shares have gained nearly 10.6% year-to-date.

TipRanks | December 1, 2022

Biotech Company Says Citadel Securities, Other Big Traders Manipulated Its Stock Price

A biotechnology company accused Citadel Securities LLC, Susquehanna International Group LLP and other Wall Street firms of driving down its stock price through a series of illicit trading tactics. In a lawsuit filed Thursday in Manhattan federal court, Northwest Biotherapeutics alleged the market makers had repeatedly engaged in “spoofing,“ where traders place orders with an intent to fool other investors about a stock’s demand and manipulate the price.

Yahoo | December 1, 2022

Northwest Biotherapeutics: Data Is Done, Just Wait For Approval

Northwest Bio published topline data on JAMA Oncology, resoundingly, I must say. Read more to see why I''m bullish on NWBO stock.

Seeking Alpha | November 23, 2022

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

/PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor…

PR Newswire | November 17, 2022

Read More 'NWBO' Stories Here

NWBO Price Returns

1-mo -11.66%
3-mo 3.60%
6-mo 3.27%
1-year -19.59%
3-year 276.57%
5-year 130.77%
YTD -8.22%
2022 12.07%
2021 -54.10%
2020 609.63%
2019 4.57%
2018 -12.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.851 seconds.